Abstract
Aim: Among urological malignancies prostate cancer most frequently leads to death. The etiology of this disease remains unknown.
Many analyses identified genes associated with increased susceptibility to prostate cancer, where changes in gene expression were associated with prostate cancer. Adaptor protein SHB is involved in apoptosis, angiogenesis and cell cycle regulation systems.
A correlation between the expression of SHB, and reduced proliferation of prostate cancer PC3 cells was detected. The aim of this work was to compare SHB expression in prostate cancer to that in benign prostate hyperplasia and to evaluate its diagnostic and prognostic potential.
Methods: In 2008-2010, isolation of mRNA from prostate cancer was performed in 53 patients. Twenty four patients with benign prostate hyperplasia were used as a control group.
The identical procedure of mRNA isolation using Oligotex Direct mRNA Midi/Maxi was used. RTPCR, expression of specific sample was visualized by electrophoresis.
Optical density was measured with densitometry For relative expression calculation, housekeeping gene GAD (glyceralde-hyde-3-phosphate dehydrogenase) was used. Results have been evaluated statistically.
Results: Statistically significant decrease in relative expression of SHB in prostate cancer tissue was detected (p 7). Conclusion: SHB is a candidate gene for prostate cancer development.
Its expression is decreased in prostate cancer compared to benign prostate hyperplasia. Its levels are decreased in locally advanced stages.